A dose-response relationship for etomidate, with some observations on cumulation

Area of Science:

• Anesthesiology
• Pharmacology
• Neurology

Background:

• Electroconvulsive therapy (ECT) requires anesthetic agents to induce sleep and minimize patient distress.
• The choice of anesthetic can impact recovery time and patient outcomes post-ECT.
• Etomidate and methohexitone are commonly used anesthetic agents for ECT.

Purpose of the Study:

• To compare the hypnotic effects and recovery profiles of different doses of etomidate versus methohexitone for ECT.
• To evaluate the dose-response relationship of etomidate on sleep duration and recovery.
• To assess the potential for cumulative effects with repeated low-dose etomidate administration.

Main Methods:

• A within-patient study involving 30 subjects undergoing ECT.
• Sleep was induced using etomidate (0.1, 0.2, 0.4 mg/kg) or methohexitone (1.5 mg/kg).
• Sleep duration and recovery of ocular muscle tone were measured to assess hypnotic effect.

Main Results:

• Increasing etomidate dosage significantly prolonged both sleep duration and recovery time.
• Etomidate 0.2 mg/kg provided sleep duration comparable to methohexitone 1.5 mg/kg but with faster late recovery.
• Repeated low-dose etomidate (0.1 mg/kg) showed minimal evidence of accumulation up to 27.5 minutes of sleep.

Conclusions:

• Etomidate offers a viable anesthetic option for ECT, with dose-dependent effects on sleep and recovery.
• Lower doses of etomidate may provide a favorable balance between adequate hypnosis and rapid patient recovery.
• Etomidate appears to have a low risk of accumulation, supporting its use for maintained anesthesia during ECT.